THC + CBD and Memory Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

EARLY_PHASE1

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-01

Study Completion Date

2026-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Memory deficits are one of the most consistently observed cognitive effects of marijuana use. There is evidence that some decrements attributable to the primary psychoactive ingredient, delta-9-tetrahydrocannabinol (THC), may be attenuated by cannabidiol (CBD). This study will help us learn more about the relationship between THC and CBD consumption with memory processes. A combination of MRI and neuropsychological tests (which are computer and paper/pencil tasks) will be used to measure the neurocognitive and behavioral impacts of THC and CBD use.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial

NCT05632627

Brain Injuries, Traumatic

COMPLETED PHASE2

Hemp-Derived Botanical Dietary Supplementation During Recovery From Brain Injury

NCT03826368

Traumatic Brain Injury

WITHDRAWN

Rehabilitation for Functional Memory Symptoms After Concussion

NCT05581810

Mild Traumatic Brain Injury Functional Neurological Disorder

COMPLETED NA

The Effect of Hypnotic Suggestion After Acquired Brain Injury or Concussion

NCT05142007

Acquired Brain Injury Concussion, Brain

COMPLETED NA

Mindfulness Intervention in Young Adults With a Concussion History

NCT05399849

Concussion, Brain Concussion Post Syndrome

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

With increased legalization and medicalization of marijuana (MJ), there is an urgent need to understand the acute effects of use. One of the most consistently observed cognitive outcomes associated with MJ use is memory dysfunction, which may have a substantial impact on daily life in individuals using MJ for recreational or medicinal purposes. Notably, there are numerous preparations of MJ with varying proportions of cannabinoids, which may differ in behavioral and cognitive effects. For instance, there is emerging evidence that acute administration of delta-9-tetrahydrocannabinol (THC), the main psychoactive constituent of MJ, hinders memory and reduces prefrontal and hippocampal functional magnetic resonance imaging (fMRI) activation, but cannabidiol (CBD) may mitigate some of these impairments. Given the role of glutamate in learning and memory, the investigators suggest that these effects may be subserved, in part, by glutamatergic mechanisms. The investigators will use magnetic resonance spectroscopy (MRS) to non-invasively measure glutamate in order to explore the neurochemical underpinnings of memory-related fMRI response changes following acute administration of THC and CBD in a randomized, double-blind, placebo-controlled, cross-over design. A total of 9 healthy participants ages 18-40 will be enrolled. Participants will first undergo one screening visit (\~4 hours), comprising informed consent, assessment of health history, psychiatric diagnoses, cognitive function, and substance use history, and a structural MRI session. This will be followed by 3 separate MJ dose visits (\~4 hours each), at which participants will complete neuroimaging after administration of one of 3 preparations of vaporized MJ in a randomized, counterbalanced, double-blinded fashion: 1) high THC and no CBD (THC), 2) high THC and high CBD (THC+CBD), and 3) no THC and no CBD (placebo MJ). As in the investigator's ongoing studies, bulk MJ plant material will be provided by the National Institute on Drug Abuse. MJ dose visits will comprise MJ administration, blood collection, MRS/fMRI scan, subjective reports, and a brief cognitive assessment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Marijuana Use Cannabis Use Cannabis Intoxication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Occasional Users - High THC and High CBD Dose

People who smoke marijuana occasionally will be given a dose of high THC high CBD marijuana at the study visit

Group Type EXPERIMENTAL

High THC/High CBD Marihuana

Intervention Type DRUG

high THC (65 mg THC) and high CBD (50 mg CBD)

Occasional Users - High THC and No CBD Dose

People who smoke marijuana occasionally will be given a dose of high THC and no CBD marijuana at the study visit

Group Type EXPERIMENTAL

High THC/No CBD Marihuana

Intervention Type DRUG

high THC (65 mg THC) and no CBD (0 mg CBD)

Occasional Users - No THC and No CBD Dose

People who smoke marijuana occasionally will be given a dose of marijuana that contains no THC or CBD

Group Type EXPERIMENTAL

No THC/No CBD Marihuana

Intervention Type DRUG

no THC (0 mg THC) and no CBD (0 mg CBD); placebo drug

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

High THC/No CBD Marihuana

high THC (65 mg THC) and no CBD (0 mg CBD)

Intervention Type DRUG

High THC/High CBD Marihuana

high THC (65 mg THC) and high CBD (50 mg CBD)

Intervention Type DRUG

No THC/No CBD Marihuana

no THC (0 mg THC) and no CBD (0 mg CBD); placebo drug

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Right-handed
* Prior MJ users (has used MJ at least once in the past year, but no more than 1x/month in the past 12 months)
* Medically healthy (as determined by medical history and treatment)
* Adequate comprehension of English in order to complete study materials
* Acceptable birth control method for women (i.e., no copper IUD or any device that is not MRI safe)

Exclusion Criteria

* Participant currently uses psychoactive medications or substances
* Psychiatric diagnoses (determined by DSM-V)
* Participant heavily or regularly uses MJ (more than 1x/month in the past year)
* Current or past substance dependence (including MJ)
* Positive urine toxicology screens
* Positive pregnancy screens
* MRI contraindications (e.g., heart pacemaker)

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes